Orthocell hits highest since Dec 2021 on regulatory nod for sale in Singapore

Orthocell

08/10/2024 01:12

** Shares of Orthocell Ltd  OCC.AX  rise as much as 10.4% to
A$0.53, their highest since Dec 17, 2021
    ** Biotechnology firm says it has received a regulatory
approval from the Health Sciences Authority in Singapore 
    ** Co says approval is for OCC to commence sales of its
nerve repair product, Remplir, in Singapore
    ** Adds, it is on track to receive U.S. FDA regulatory
clearance in Q1 CY25
    ** OCC stock up 17.1% YTD

 (Reporting by Ayushman Ojha in Bengaluru)
 ((Ayushman.ojha@thomsonreuters.com))